Recent Analysts’ Ratings Changes for Medtronic (MDT)

by · The Cerbat Gem

A number of firms have modified their ratings and price targets on shares of Medtronic (NYSE: MDT) recently:

  • 4/7/2026 – Medtronic had its price target lowered by Citigroup Inc. from $117.00 to $110.00. They now have a “buy” rating on the stock.
  • 4/6/2026 – Medtronic had its price target lowered by Evercore Inc from $115.00 to $108.00. They now have an “outperform” rating on the stock.
  • 4/6/2026 – Medtronic had its price target lowered by Stifel Nicolaus from $105.00 to $95.00. They now have a “hold” rating on the stock.
  • 4/6/2026 – Medtronic had its price target lowered by Argus from $125.00 to $115.00. They now have a “buy” rating on the stock.
  • 4/1/2026 – Medtronic had its price target raised by Barclays PLC from $118.00 to $120.00. They now have an “overweight” rating on the stock.
  • 4/1/2026 – Medtronic had its price target lowered by Piper Sandler from $105.00 to $91.00. They now have a “neutral” rating on the stock.
  • 3/28/2026 – Medtronic was upgraded by Wall Street Zen from “hold” to “buy”.
  • 3/26/2026 – Medtronic had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $120.00 price target on the stock.
  • 3/10/2026 – Medtronic had its “outperform” rating reaffirmed by Leerink Partners. They now have a $119.00 price target on the stock.
  • 3/10/2026 – Medtronic had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $120.00 price target on the stock.
  • 3/1/2026 – Medtronic was downgraded by Wall Street Zen from “buy” to “hold”.
  • 2/27/2026 – Medtronic had its price target lowered by Daiwa Securities Group Inc. from $117.00 to $115.00. They now have a “buy” rating on the stock.
  • 2/21/2026 – Medtronic was upgraded by Wall Street Zen from “hold” to “buy”.
  • 2/18/2026 – Medtronic had its “overweight” rating reaffirmed by Barclays PLC. They now have a $118.00 price target on the stock.
  • 2/18/2026 – Medtronic had its price target lowered by Truist Financial Corporation from $107.00 to $103.00. They now have a “hold” rating on the stock.
  • 2/18/2026 – Medtronic was upgraded by Mizuho to “strong-buy”.
  • 2/18/2026 – Medtronic had its price target lowered by JPMorgan Chase & Co. from $105.00 to $100.00. They now have a “neutral” rating on the stock.
  • 2/18/2026 – Medtronic had its price target lowered by Leerink Partners from $120.00 to $119.00. They now have an “outperform” rating on the stock.
  • 2/18/2026 – Medtronic had its price target lowered by Robert W. Baird from $103.00 to $100.00. They now have a “neutral” rating on the stock.
  • 2/17/2026 – Medtronic had its price target lowered by Needham & Company LLC from $121.00 to $120.00. They now have a “buy” rating on the stock.
  • 2/13/2026 – Medtronic is now covered by Barclays PLC. They set an “overweight” rating and a $116.00 price target on the stock.
  • 2/9/2026 – Medtronic was upgraded by Needham & Company LLC from “hold” to “buy”. They now have a $121.00 price target on the stock.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be issued a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s payout ratio is 79.11%.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.26% of the company’s stock.

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Read More